Targeting of nuclear Factor-κB and proteasome by dithiocarbamate complexes with metals

被引:121
|
作者
Cvek, B. [1 ]
Dvorak, Z. [1 ]
机构
[1] Palacky Univ, Fac Med & Dent, Dept Med Chem & Biochem, CR-77147 Olomouc, Czech Republic
关键词
disulfiram; diethyldithiocarbamate (DDTC); pyrrolidinedithiocarbamate (PDTC); metal dithiocarbamates; NF-kappa B; proteasome; JAMM;
D O I
10.2174/138161207782110390
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-kappa B (NF-kappa B) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-kappa B plays a central role in the immune system and is described as major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-kappa B pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-kappa B signal transduction were recognized, Additionally, proteasome system was found to be a key player in NF-kappa B pathway and is an attractive target for anticancer drug development Collectively, the capability of dithiocarbamates to inhibit NF-kappa B and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-kappa B signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
引用
收藏
页码:3155 / 3167
页数:13
相关论文
共 50 条
  • [41] Tumor necrosis factor-α-inducible IκBα proteolysis mediated by cytosolic m-calpain -: A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-κB activation
    Han, YQ
    Weinman, S
    Boldogh, I
    Walker, RK
    Brasier, AR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) : 787 - 794
  • [42] Shikonin Promotes Skin Cell Proliferation and Inhibits Nuclear Factor-κB Translocation via Proteasome Inhibition In Vitro
    Yan, Yan
    Furumura, Minao
    Gouya, Takako
    Iwanaga, Atsufumi
    Teye, Kwesi
    Numata, Sanae
    Karashima, Tadashi
    Li, Xiao-Guang
    Hashimoto, Takashi
    CHINESE MEDICAL JOURNAL, 2015, 128 (16) : 2228 - 2233
  • [43] Shikonin Promotes Skin Cell Proliferation and Inhibits Nuclear Factor-κB Translocation via Proteasome Inhibition In Vitro
    Yan Yan
    Furumura Minao
    Gouya Takako
    Iwanaga Atsufumi
    Teye Kwesi
    Numata Sanae
    Karashima Tadashi
    Li Xiao-Guang
    Hashimoto Takashi
    中华医学杂志英文版, 2015, 128 (16) : 2228 - 2233
  • [44] Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection:: role of nuclear factor-κB
    La Frazia, Simone
    Amici, Carla
    Sontoro, M. Gabriella
    ANTIVIRAL THERAPY, 2006, 11 (08) : 995 - 1004
  • [45] Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway
    Lin, Yvonne G.
    Kunnumakkara, Ajaikumar B.
    Nair, Asha
    Merritt, William M.
    Han, Liz Y.
    Armaiz-Pena, Guillermo N.
    Kamat, Aparna A.
    Spannuth, Whitney A.
    Gershenson, David M.
    Lutgendorf, Susan K.
    Aggarwal, Bharat B.
    Sood, Anil K.
    CLINICAL CANCER RESEARCH, 2007, 13 (11) : 3423 - 3430
  • [46] Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation
    Iwase, Ryota
    Haruki, Koichiro
    Fujiwara, Yuki
    Furukawa, Kenei
    Shiba, Hiroaki
    Uwagawa, Tadashi
    Misawa, Takeyuki
    Ohashi, Toya
    Yanaga, Katsuhiko
    JOURNAL OF SURGICAL RESEARCH, 2013, 184 (01) : 605 - 612
  • [47] Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
    Tas, Sander W.
    Vervoordeldonk, Margriet J. B. M.
    Tak, Paul P.
    CURRENT GENE THERAPY, 2009, 9 (03) : 160 - 170
  • [48] Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastases
    Saad, Fred
    Markus, Richard
    Goessl, Carsten
    BJU INTERNATIONAL, 2008, 101 (09) : 1071 - 1075
  • [49] Nuclear Factor-κb Polymorphism And Risk Of COPD
    Young, R. P.
    Hopkins, R. J.
    Hay, B.
    Gamble, G. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [50] Control of lymphocyte development by nuclear factor-κB
    Siebenlist, U
    Brown, K
    Claudio, E
    NATURE REVIEWS IMMUNOLOGY, 2005, 5 (06) : 435 - 445